MedTrace Logo

Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment

NCT07741981 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2026-08-03

No results posted yet for this study

Summary

The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments. Involving complex processes within the brain and peripheral immune system, inflammation may lead to imbalance of neurotransmitter systems and synaptic plasticity and directly contribute to the psychiatric symptoms observed in conditions such as depression, bipolar disorder (BD) and schizophrenia (SCZ).

Studies show that treatment-resistant depression (TRD) is associated with elevated levels of inflammatory markers in the blood, which are linked to a lower response to conventional antidepressants. Interventions that modulate this inflammatory response, such as immunomodulatory treatments or therapies targeting pro-inflammatory cytokines, have demonstrated beneficial effects by reducing symptoms and improving patients' quality of life.

A thorough understanding of the links between inflammation and treatment resistance therefore paves the way for innovative therapeutic strategies. These approaches could transform current practices by offering more personalized and effective solutions for patients suffering from chronic and resistant psychiatric disorders.

Conditions

  • Schizophrenia
  • Treatment Resistant Depression (TRD)
  • Bipolar Disorder (BD)
  • Catatonia
  • Obsessive Compulsive Disorder (OCD)

Interventions

BIOLOGICAL

Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales

the biomarker research involves different biological sampling : blood, stool, cerebrospinal fluid, skin

Sponsors & Collaborators

  • GHU Paris Psychiatry & Neurosciences

    collaborator OTHER

  • Centre Hospitalier St Anne

    lead OTHER

Principal Investigators

  • Anne-Cécile PETIT, MD, PhD · GHU Paris Psychiatry & Neurosciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2036-10-01
Completion
2038-08-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07741981 on ClinicalTrials.gov